Provided by Tiger Fintech (Singapore) Pte. Ltd.

Protagonist Therapeutics

42.97
-0.9500-2.16%
Post-market: 42.970.00000.00%16:08 EDT
Volume:671.23K
Turnover:29.31M
Market Cap:2.66B
PE:49.82
High:45.43
Open:44.15
Low:42.85
Close:43.92
Loading ...

Protagonist Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
04 Mar

Protagonist Therapeutics: Positive VERIFY Trial Results and Promising Financial Prospects Justify Buy Rating

TIPRANKS
·
04 Mar

Protagonist Therapeutics price target raised to $73 from $67 at BTIG

TIPRANKS
·
04 Mar

News Flash: 10 Analysts Think Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Earnings Are Under Threat

Simply Wall St.
·
04 Mar

Protagonist Therapeutics Price Target Maintained With a $54.00/Share by HC Wainwright & Co.

Dow Jones
·
04 Mar

Protagonist Therapeutics’ Rusfertide: A Promising Blockbuster in the Polycythemia Vera Market with Strong Buy Rating

TIPRANKS
·
04 Mar

Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer

Benzinga
·
04 Mar

Protagonist Therapeutics Inc : JP Morgan Raises Target Price to $57 From $53

THOMSON REUTERS
·
04 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Melco Resorts, Chipotle, Allegro

Reuters
·
03 Mar

Protagonist Therapeutics: Buy Rating Affirmed on Rusfertide’s Phase 3 Success and Market Potential

TIPRANKS
·
03 Mar

Protagonist Therapeutics: Strong Buy Rating Backed by Promising Phase 3 Results and Robust Financial Outlook

TIPRANKS
·
03 Mar

Stock Track | Protagonist Therapeutics Soars 12.13% as Blood Cancer Drug Rusfertide Succeeds in Phase 3 Trial, Meeting All Key Endpoints

Stock Track
·
03 Mar

Protagonist Therapeutics Shares up 9.8% as Blood Cancer Treatment Succeeds Late-Stage Study

THOMSON REUTERS
·
03 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, SolarEdge ,Protagonist

Reuters
·
03 Mar

Protagonist, Takeda Say Phase 3 Study of Rusfertide Meets Endpoints in Polycythemia Vera

MT Newswires Live
·
03 Mar

BUZZ-Protagonist climbs as blood cancer treatment succeeds late-stage study

Reuters
·
03 Mar

BRIEF-Protagonist And Takeda Announce Positive Topline Results From Phase 3 Verify Study Of Rusfertide

Reuters
·
03 Mar

Stock Track | Protagonist Therapeutics Soars 6.41% Pre-Market as Rusfertide Succeeds in Phase 3 PV Trial

Stock Track
·
03 Mar

Protagonist Therapeutics Inc - Rusfertide Generally Well Tolerated With No New Safety Findings

THOMSON REUTERS
·
03 Mar

Protagonist and Takeda Announce Positive Topline Results From Phase 3 Verify Study of Rusfertide in Patients With Polycythemia Vera

THOMSON REUTERS
·
03 Mar